Analysts Issue Forecasts for Cytosorbents Corp’s FY2020 Earnings (CTSO)
Cytosorbents Corp (NASDAQ:CTSO) – Equities research analysts at Zacks Investment Research lowered their FY2020 earnings per share estimates for Cytosorbents Corp in a report released on Monday. Zacks Investment Research analyst B. Marckx now anticipates that the medical research company will earn ($0.01) per share for the year, down from their prior estimate of $0.03.
Cytosorbents Corp (NASDAQ:CTSO) last released its earnings results on Monday, May 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.06. The company had revenue of $3.11 million for the quarter, compared to analyst estimates of $2.99 million. Cytosorbents Corp had a negative return on equity of 193.13% and a negative net margin of 120.04%.
TRADEMARK VIOLATION NOTICE: “Analysts Issue Forecasts for Cytosorbents Corp’s FY2020 Earnings (CTSO)” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/analysts-issue-forecasts-for-cytosorbents-corps-fy2020-earnings-ctso/1287438.html.
Other equities analysts have also recently issued reports about the company. Maxim Group restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents Corp in a research report on Tuesday, April 25th. B. Riley reaffirmed a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corp in a research note on Tuesday, April 11th. Aegis reaffirmed a “buy” rating on shares of Cytosorbents Corp in a research note on Tuesday, March 7th. Finally, HC Wainwright lifted their price target on Cytosorbents Corp from $11.50 to $13.00 and gave the stock a “buy” rating in a research note on Monday, March 6th. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $13.45.
Cytosorbents Corp (NASDAQ:CTSO) remained flat at $4.10 during mid-day trading on Tuesday. The company’s stock had a trading volume of 107,006 shares. Cytosorbents Corp has a 1-year low of $4.00 and a 1-year high of $6.90. The firm’s 50 day moving average price is $4.72 and its 200 day moving average price is $5.29. The company’s market cap is $115.24 million.
A number of large investors have recently modified their holdings of CTSO. Sabby Management LLC purchased a new stake in shares of Cytosorbents Corp during the first quarter valued at about $990,000. Geode Capital Management LLC raised its stake in shares of Cytosorbents Corp by 0.5% in the first quarter. Geode Capital Management LLC now owns 126,883 shares of the medical research company’s stock valued at $570,000 after buying an additional 606 shares during the period. Vanguard Group Inc. raised its stake in shares of Cytosorbents Corp by 3.9% in the first quarter. Vanguard Group Inc. now owns 567,116 shares of the medical research company’s stock valued at $2,552,000 after buying an additional 21,312 shares during the period. Cowen Group Inc. purchased a new stake in shares of Cytosorbents Corp during the first quarter valued at about $248,000. Finally, Segantii Capital Management Ltd raised its stake in shares of Cytosorbents Corp by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares during the period. 6.07% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.